Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading
FDA approves Quadracel vaccine to protect young children from life-threatening diseases

FDA approves Quadracel vaccine to protect young children from life-threatening diseases

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration has approved use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age. [More]
IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

Intravenous (IV) cosyntropin therapy was equivalent to epidural blood patch (EBP) in relieving pain from post-dural puncture headache (PDPH) with potential for fewer complications and lower costs, data from a randomized, controlled trial showed. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Migraine headaches with auras may increase risk of stroke

Migraine headaches with auras may increase risk of stroke

People who suffer migraine headaches with auras are at roughly double the risk of suffering the most common type of stroke. [More]
Patients with carpal tunnel syndrome twice as likely to have migraine headaches, shows study

Patients with carpal tunnel syndrome twice as likely to have migraine headaches, shows study

Patients with carpal tunnel syndrome are more than twice as likely to have migraine headaches, reports a study in Plastic and Reconstructive Surgery--Global Open, the official open-access medical journal of the American Society of Plastic Surgeons (ASPS). [More]
Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. [More]
Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T. [More]
AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

The American Academy of Pain Medicine is pleased to announce its 2015 Pain Medicine Fellowship Excellence Award Recipients in recognition of a Pain Medicine Fellowship Program that provides an exceptional learning experience to its fellows, preparing them to deliver the highest standard of care to patients with pain. [More]
Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. [More]
Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions. [More]
Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the commercial availability of NATESTO (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
Meta-analysis finds that high dose zinc acetate lozenges may help reduce duration of cold symptoms

Meta-analysis finds that high dose zinc acetate lozenges may help reduce duration of cold symptoms

According to a meta-analysis published in BMC Family Practice, high dose zinc acetate lozenges shortened the duration of common-cold associated nasal discharge by 34%, nasal congestion by 37%, scratchy throat by 33%, and cough by 46%. [More]
New device can detect cyanide exposure within 70 seconds

New device can detect cyanide exposure within 70 seconds

A victim of cyanide poisoning can die within 30 minutes. The diagnostic test to determine cyanide exposure takes 24 hours. [More]
FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). [More]

electroCore’s gammaCore device effective in helping patients prevent, treat cluster headache

A twelve-month open-label study in the March issue of the journal Neurology, reports that electroCore’s non-invasive Vagus Nerve stimulation (nVNS) device, gammaCore, is practical and effective as an acute and preventative treatment in cluster headache. Seventy-nine percent of patients who completed the trial (15 out of 19) reported an overall improvement in their condition. [More]
Dengue fever circulating in urban areas of West Africa

Dengue fever circulating in urban areas of West Africa

Misdiagnosis of febrile illnesses as malaria is a continuing problem in Africa. A new study shows that in Ghana, dengue fever is circulating in urban areas and going undiagnosed. The authors of the study hope to use the findings to launch a widespread initiative to better understand acute undifferentiated febrile illnesses in West Africa. [More]
FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. [More]
Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat inhaler from five Phase III trials from the UniTinA-asthma program at the 2015 American Academy of Allergy, Asthma & Immunology Annual Meeting in Houston, Texas. [More]
Virginia Tech biochemists identify potential drug target against sleeping sickness

Virginia Tech biochemists identify potential drug target against sleeping sickness

Virginia Tech biochemists are trying to deliver a stern wake-up call to the parasite that causes sleeping sickness. [More]
Advertisement
Advertisement